EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma

Frontiers in Bioscience

Volumn 15, Issue 1, 2010, Pages 65-72

  Kaneko, Kazuhiro ^a,b   Kumekawa, Yosuke ^b   Makino, Reiko ^b   Nozawa, Hisako ^b   Hirayama, Yuichi ^b   Kogo, Mari ^c   Konishi, Kazuo ^b   Katagiri, Atsushi ^b   Kubota, Yutaro ^b   Muramoto, Takashi ^b   Kushima, Miki ^b   Ohmori, Tohru ^b   Oyama, Tsunehiro ^d   Kagawa, Norio ^e   Ohtsu, Atsushi ^a   Imawari, Michio ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHOWA UNIVERSITY   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EGFR; Esophageal squamous cell carcinoma; Prognosis; SNP

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; PROTEIN P53; TUMOR MARKER;

AGED; ARTICLE; ESOPHAGUS TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; RADIOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77951223020     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3607     Document Type: Article

References (45)

1. D.M. Parkin, F.I. Bray & S.S. Devesa. Cancer burden in the year 2000. The global picture. Eur J Cancer, 37(supple 8), S4-66 (2001).
2. Registration Committee for Esophageal Cancer (ed). Comprehensive registry of esophageal cancer in Japan: The Japan Society for Esophageal Diseases. http://plaza.umin.ac.jp/70~jsed/.
3. Y.G. Goan, H.C. Chang, H.K. Hsu & Y.P. Chou. An audit of surgical outcomes of esophageal squamous cell carcinoma. Eur J Cardio-Thorac, 31, 536-44 (2007).
4. S. Law, D.L. Kwoung, K.F. Kwort, K.H. Wong, K.M. Chu, J.S. Sham & J. Wong. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg, 238, 339-47 (2003).
5. M.B. Orringer, B. Marshal & M.D. Iannettoni. Transhiatal esophagectomy: clinical experience and refinement. Ann Surg, 230, 392-400 (1999).
6. N. Ando, S. Ozawa, Y. Kitagawa, Y. Shinozawa & M. Kitajima. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg, 232, 225-32 (2000). (Pubitemid 30616724)
7. A. Peracchia, L. Bonavina, A. Roul & H. Stein. Esophageal cancer: a European perspective Recent Results. Cancer Res 2000;155:119-22.
8. L.R. Coia. Chemoradioation as primary management of esophageal cancer. Semin Oncol, 21, 483-92 (1994). (Pubitemid 24256840)
9. A.A. Forastiere, M.B. Orringer, C. Perez-Tamayo, S.G. Urba & M. Zahurak. Preoperative chemoradiation followed by trans-hiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol, 11, 1118-23 (1993). (Pubitemid 23163353)
10. A. Ohtsu, S. Yoshida, N. Boku, T. Fujii, Y. Miyata, K. Hosokawa, I. Koba, W. Shimizu & T. Ogino. Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol, 25, 261-6 (1995).
11. A. Ohtsu, N. Boku, K. Muro, K. Chin, M. Muto, S. Yoshida, M. Satake, S. Ishikura, T. Ogino, Y. Miyata, S. Seki, K. Kaneko & A. Nakamura. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol, 17, 2915-21 (1999). (Pubitemid 29415253)
12. K. Kaneko, H. Ito, K. Konishi, T. Kurahashi, T. Ito, A. Katagiri, T. Yamamoto, T. Kitahara, Y. Mizutani, A. Ohtsu & K. Mitamura. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer, 88, 18-24 (2003). (Pubitemid 36241212)
13. A.J. Levine. p53, cellular gatekeeper for growth and divison. Cell, 88, 323-31 (1997). (Pubitemid 27131374)
14. M. Waller. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res, 292, 435-45 (1998).
15. G. Carpenter & S. Cohen. Epidermal growth factor. J Biol Chem, 265, 7709-12 (1990). (Pubitemid 20158927)
16. F.X. Real, W.J. Rettig, P.G. Chesa, M.R. Melamed, L.J. Old & J. Mendelsohn. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res, 46, 4726-31 (1986). (Pubitemid 16000351)
17. F. Ciardiello & G. Tortora. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 7, 2958-70 (2001). (Pubitemid 32963812)
18. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman & D.A. Haber. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39 (2004). (Pubitemid 38637993)
19. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson & M. Meyerson. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500 (2004). (Pubitemid 38720929)
20. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris & H. Varmus. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101, 13306-11 (2004). (Pubitemid 39209661)
21. S.F. Huang, H.P. Liu, L.H. Li, Y.C. Ku, Y.N. Fu, H.Y. Tsai, Y.T. Chen, Y.F. Lin, W.C. Chang, H.P. Kuo, Y.C. Wu, Y.R. Chen & S.F. Tsai. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res, 10, 8195-203 (2004).
22. T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, T. Takahashi & T. Mitsudomi. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res, 64, 8919-23 (2004). (Pubitemid 39665498)
23. H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, I.I. Wistuba, K.M. Fong, H. Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Z. Feng, J.A. Roth, J. Herz, J.D. Minna & A.F. Gazdar. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 97, 339-46 (2005). (Pubitemid 40425952)
24. M. Tokumo, S. Toyooka, K. Kiura, H. Shigematsu, K. Tomii, M. Aoe, K. Ichimura, T. Tsuda, M. Yano, K. Tsukuda, M. Tabata, H. Ueoka, M. Tanimoto, H. Date, A.F. Gazdar & N. Shimizu. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in nonsmall cell lung cancers. Clin Cancer Res, 11, 1167-73 (2005). (Pubitemid 40175767)
25. E.A. Perez. The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies. Curr Oncol Rep, 3, 516-22 (2001).
26. A.W. Hemming, N.L. Davis, A. Kluftinger, B. Robinson, N.F. Quenville, B. Liseman & J. LeRiche. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol, 51, 147-52 (1992).
27. L. Gibault, J.P. Metges, V. Conan-Charlet, P. Lozac'h, M. Robaszkiewicz, C. Bessaguet, N. Lagarde & A. Volant. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer, 93, 107-15 (2005). (Pubitemid 41076258)
28. R.I. Nicholson, I.R. Hutcheson & M.E. Harper. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer, 8, 175-82 (2001). (Pubitemid 32947639)
29. Y. Itakura, H. Sasano, C. Shiga, Y. Furukawa, K. Shiga, S. Mori & H. Nagura. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer, 74, 795-804 (1994). (Pubitemid 24237457)
30. A. Katagiri, K. Kaneko, K. Konishi, H. Ito, M. Kushima & K. Mitamura. Lugol staining pattern in background epithelium of patients with esophageal squamous cell carcinoma. Hepatogastroenterol, 51, 713-7 (2004). (Pubitemid 38590947)
31. S.E. Goelz, S.R. Hamilton & B. Vogelstein. Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun, 130, 118-26 (1985). (Pubitemid 15249008)
32. Single Nucleotide Polymorphism: SNP linked to Gene EGFR (geneID:1956) Via Contig Annotation. http://www.ncbi.nlm.nih.gov/SNP/snp-ref1.cgi?locusId=1956.
33. M.S. Greenblatt, W.P. Bennett, M. Hollstein & C.C. Harris. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res, 54, 4855-78 (1994). (Pubitemid 24289415)
34. J.E. Choi, S.H. Park, K.M. Kim, W.K. Lee, S. Kam, S.I. Cha, C.H. Kim, Y.M. Kang, Y.C. Kim, S.B. Han, T.H. Jung & J.Y. Park. Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a casecontrol study. BMC Cancer, 7, 199 (2007).
35. J.G. Paez, P.A. Janne, J.C. Lee, T. Sean, G. Heidi, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson & M. Meyerson. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500 (2004). (Pubitemid 38720929)
36. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman & D.A. Haber. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39 (2004). (Pubitemid 38637993)
37. K.S. Kim, J.Y. Jeong, Y.C. Kim, K.J. Na, Y.H. Kim, S.J. Ahn, S.M. Baek, C.S. Park, C.M. Park, Y.I. Kim, S.C. Lim & K.O. Park. Predictors of the Response to Gefitinib in Refractory Non-Small Cell Lung Cancer. Clin Cancer Res, 11, 2244-51 (2005).
38. M. Shahbazi, V. Pravica, N. Nasreen, N. Fakhoury, A. Fryer, R. Strange, P. Hutchinson, J. Osborne, J. Lear & A. Smith. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet, 359, 397-401 (2002). (Pubitemid 34158948)
39. J. Bange, D. Prechtl, Y. Cheburkin, K. Specht, N. Harbeck, M. Schmitt, T. Knyazeva, S. Müller, S. Gärtner, I. Sures, H. Wang, E. Imyanitov, H.U. Häring, P. Knayzev, S. Iacobelli, H. Höfler & A. Ullrich. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res, 62, 840-7 (2002). (Pubitemid 34126962)
40. R. McKean-Cowdin, L.N. Kolonel, M.F. Press, M.C. Pike & B.E. Henderson. Germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res, 61, 8393- 4 (2001). (Pubitemid 33131112)
41. P. Iughetti, O. Suzuki, P.H. Godoi, V. A. Alves, A. L. Sertié, T. Zorick, F. Soares, A. Camargo, E.S. Moreira, C. di Loreto, C.A. Moreira-Filho, A. Simpson, G. Oliva & M.R. Passos-Bueno. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res, 61, 7375-8 (2001). (Pubitemid 32995018)
42. E. Papadopoulou, G. Tripsianis, K. Anagnostopoulos, I. Tentes, S. Kakolyris, G. Galazios, E. Sivridis, K. Simopoulos & A. Kortsaris. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Neoplasma, 55, 113-21 (2008).
43. M. Hanawa, S. Suzuki, Y. Dobashi, T. Yamane, K. Kono, N. Enomoto & A. Ooi. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer, 118, 1173-80 (2006). (Pubitemid 43185604)
44. P. Sunpaweravong, S. Sunpaweravong, P. Puttawibul, W. Mitarnun, C. Zeng, A.E. Barón, W. Franklin, S. Said & M. Varella-Garcia. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol, 131, 111-9 (2005). (Pubitemid 40192936)
45. Q. Wei, L. Chen, L. Sheng, H. Nordgren, K. Wester & J. Carlsson. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastasis. Int J Oncol, 31, 493-9 (2007).